|
NSL1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.231900137455E-10 |
| Normal-vs-Stage3 |
7.43849426498855E-15 |
| Normal-vs-Stage4 |
1.66144875635155E-12 |
| Stage1-vs-Stage2 |
9.327600E-01 |
| Stage1-vs-Stage3 |
1.335020E-01 |
| Stage1-vs-Stage4 |
3.025600E-02 |
| Stage2-vs-Stage3 |
3.733400E-01 |
| Stage2-vs-Stage4 |
1.154620E-01 |
| Stage3-vs-Stage4 |
4.054200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.20410000004068E-06 |
| Normal-vs-Asian |
4.19219999825415E-08 |
| Caucasian-vs-AfricanAmerican |
2.684800E-01 |
| Caucasian-vs-Asian |
6.788200E-02 |
| AfricanAmerican-vs-Asian |
8.254800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.33226762955019E-15 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
4.425000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
4.44089209850063E-16 |
| Normal-vs-Age(61-80Yrs) |
1.74404934938366E-12 |
| Normal-vs-Age(81-100Yrs) |
7.761800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.438200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.734200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.626000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.224000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.566800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.054800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.142400E-02 |
| Classical-VS-Follicular |
7.486000E-02 |
| Classical-VS-Other |
4.295600E-01 |
| Classical-VS-Normal |
1.62481139653892E-12 |
| Tall-VS-Follicular |
3.850600E-01 |
| Tall-VS-Other |
7.711200E-01 |
| Tall-VS-Normal |
8.88800144593915E-12 |
| Follicular-VS-Other |
8.600400E-01 |
| Follicular-VS-Normal |
1.68165481539972E-12 |
| Other-VS-Normal |
2.639900E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.22044604925031E-16 |
| Normal-vs-N1 |
1.47215573065296E-13 |
| N0-vs-N1 |
2.971800E-01 |
|
|
